Rhythm Pharmaceuticals Announces New Employment Inducement Grants
April 06, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals kondigt overname aan van Xinvento B.V. en portfolio van Investigational Therapeutics
April 04, 2023 03:00 ET
|
Rhythm Pharmaceuticals, Inc.
– Bedrijf dat zich richt op zeldzame ziekten bezig met preklinische ontwikkeling voor congenitaal hyperinsulinisme – – De overname is zeer strategisch, sluit aan bij de huidige focus van Rhythm op...
Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide
March 27, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food – - Company also announces publication...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
March 06, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
March 01, 2023 07:00 ET
|
Rhythm Pharmaceuticals, Inc.
-- IMCIVREE® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- -- IMCIVREE now available in eight ex-U.S. markets;...
Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
February 27, 2023 08:45 ET
|
Rhythm Pharmaceuticals, Inc.
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new...
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023
February 21, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
February 08, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome
January 23, 2023 08:00 ET
|
Rhythm Pharmaceuticals, Inc.
- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide - - Analysis published in Orphanet...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
January 05, 2023 16:01 ET
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...